Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Transfusion in sickle cell anemia].

S Germain1, L Brahimi, P Rohrlich

  • 1Site Transfusionnel Armand Trousseau ETS-APHP, Paris, France.

Pathologie-Biologie
|March 19, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiscale Imaging to Monitor Functional SHED-Supported Engineered Vessels.

Journal of dental research·2024
Same author

The KMT2A recombinome of acute leukemias in 2023.

Leukemia·2023
Same author

Ozone effect on the inflammatory and proteomic profile of human macrophages and airway epithelial cells.

Respiratory physiology & neurobiology·2022
Same author

[Erythrapheresis in children with sickle cell disease, experience of a paediatric apheresis unit].

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2021
Same author

CNS-3 status remains an independent adverse prognosis factor in children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: Results of EORTC Children Leukemia Group study 58951.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2021
Same author

Beta-blocker therapy and risk of vascular dementia: A population-based prospective study.

Vascular pharmacology·2020

Blood transfusion (BT) therapy for sickle cell disease is being re-evaluated due to new treatments and safety concerns. Benefits must be weighed against risks like infections and iron overload.

Area of Science:

  • Hematology
  • Transfusion Medicine
  • Sickle Cell Disease Management

Background:

  • Blood transfusion (BT) is a cornerstone therapy for sickle cell disease (SCD) complications.
  • New treatments like hydroxyurea and bone marrow transplantation, alongside safety concerns, necessitate a re-evaluation of BT indications.
  • Risks including infections, alloimmunization, and iron overload require careful consideration against transfusion benefits.

Purpose of the Study:

  • To critically reappraise the indications and modalities of blood transfusion therapy in sickle cell disease.
  • To evaluate the benefits versus risks of simple and exchange blood transfusions in various SCD scenarios.
  • To highlight advances in minimizing BT-related complications.

Main Methods:

  • Review of current literature and clinical practices regarding blood transfusion in SCD.

Related Experiment Videos

  • Analysis of simple versus exchange blood transfusion protocols for acute and chronic management.
  • Assessment of strategies to mitigate transfusion-associated risks.

    • Main Results:

    • Simple and exchange BT are crucial for managing acute SCD complications like severe anemia, hypovolemia, vaso-occlusive crisis, and infection.
    • Long-term exchange BT programs can prevent stroke recurrence in patients ineligible for bone marrow transplantation.
    • BT is used in pregnancy, perioperative settings, and for preventing vaso-occlusive crisis recurrence, though its value is debated in some cases.

    Conclusions:

    • Careful benefit-risk assessment is essential for each BT indication in SCD.
    • Advances in transfusion techniques and product selection reduce complications like alloimmunization, infections, and iron overload.
    • Optimizing BT therapy involves critical appraisal of need, appropriate product selection, and modified techniques to minimize donor exposure.